Literature DB >> 25316229

Correlation of Th17 cells and CD4⁺CD25⁺ regulatory T cells with clinical parameters in patients with systemic sclerosis.

Nan Jiang1, Mengtao Li2, Xiaofeng Zeng3.   

Abstract

BACKGROUND: Systemic sclerosis (SSc) is an autoimmune disease that has three major components: inflammation, fibrosis, and vasculopathy. T-helper 17 cell (Th17) and regulatory T cell (Treg) are considered to be critical for autoimmune disease pathogenesis. The role of Th17 and Treg in SSc is still unclear. The aim of this study was to detect the presence of Th17s and CD4(+)CD25(+) Tregs in peripheral blood samples from SSc patients and to investigate the possible roles of these two T cell subsets in SSc pathogenesis.
METHODS: Th17s (CD4 and IL-17 positive) and CD4(+)CD25(+) Tregs (CD4, CD25 and Foxp3 positive) in the peripheral blood mononuclear cells of 53 SSc patients and 27 healthy controls were counted by flow cytometry. The differences between SSc and control patients were analyzed. Clinical parameters, including disease duration, duration of the second symptoms, Modified Rodnan Skin Score (MRSS), anti-topoisomerase I antibody, anti-U1 ribonucleoprotein (RNP) antibody, systemic involvements, pulmonary function test (PFT) and high resolution computed tomography (HRCT) score were prospectively collected following EUSTAR (EULAR scleroderma trial and research group) protocols. The correlations between the experimental and clinical data were investigated.
RESULTS: The ratio of Th17 in SSc patients was significantly elevated compared to healthy controls (8.74% vs. 4.41%, P < 0.001). The amount of Th17 was positively correlated with disease duration (R = 0.531, P = 0.013) and duration of the second symptoms (R = 0.505, P = 0.023). The ratio of CD4(+)CD25(+) Treg in SSc patients also significantly differed from the healthy controls (3.04% vs. 2.24%, P = 0.018). Elevated Tregs were more frequently observed in patients with a high interstitial lung disease (ILD) score on computed tomography (24/36) compared with patients with normal ILD scores (4/12, P = 0.043). Elevated Tregs were also more often observed in patients with low carbon monoxide diffusing capacity (DLCO) (24/34) compared with patients with normal DLCO (4/11, P = 0.042).
CONCLUSIONS: T cell abnormalities are remarkable in systemic sclerosis. Th17s proliferate and their numbers increase with lengthened disease duration. Th17s might participate in both inflammation and fibrosis by secreting IL-17. CD4(+)CD25(+) Tregs also proliferate in SSc and may play important roles in promoting fibrosis.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25316229

Source DB:  PubMed          Journal:  Chin Med J (Engl)        ISSN: 0366-6999            Impact factor:   2.628


  11 in total

Review 1.  Treg cells in autoimmunity: from identification to Treg-based therapies.

Authors:  Lisa Göschl; Clemens Scheinecker; Michael Bonelli
Journal:  Semin Immunopathol       Date:  2019-04-05       Impact factor: 9.623

2.  Higher levels of serum interleukin-35 are associated with the severity of pulmonary fibrosis and Th2 responses in patients with systemic sclerosis.

Authors:  Jie Tang; Ling Lei; Jie Pan; Cheng Zhao; Jing Wen
Journal:  Rheumatol Int       Date:  2018-05-30       Impact factor: 2.631

Review 3.  Photopheresis: Advances and Use in Systemic Sclerosis.

Authors:  Xiaolong Alan Zhou; Jaehyuk Choi
Journal:  Curr Rheumatol Rep       Date:  2017-06       Impact factor: 4.592

4.  Effect of TGF-β1 on blood CD4+CD25high regulatory T cell proliferation and Foxp3 expression during non-small cell lung cancer blood metastasis.

Authors:  Yi Hu; Weibo Qi; Li Sun; Hui Zhou; Biliu Zhou; Zhiping Yang
Journal:  Exp Ther Med       Date:  2018-06-13       Impact factor: 2.447

5.  Increased IL-35 serum levels in systemic sclerosis and association with pulmonary interstitial involvement.

Authors:  Andréa Tavares Dantas; Sayonara Maria Calado Gonçalves; Michelly Cristiny Pereira; Rafaela Silva Guimarães Gonçalves; Cláudia Diniz Lopes Marques; Moacyr Jesus Barreto de Melo Rego; Ivan da Rocha Pitta; Angela Luzia Branco Pinto Duarte; Maira Galdino da Rocha Pitta
Journal:  Clin Rheumatol       Date:  2015-07-11       Impact factor: 2.980

Review 6.  Interleukin-35: a Potential Therapeutic Agent for Autoimmune Diseases.

Authors:  Shi-Yang Guan; Rui-Xue Leng; Muhammad Imran Khan; Humera Qureshi; Xiang-Pei Li; Dong-Qing Ye; Hai-Feng Pan
Journal:  Inflammation       Date:  2017-02       Impact factor: 4.092

Review 7.  Regulatory T Cells in Systemic Sclerosis: a Comprehensive Review.

Authors:  Gleb Slobodin; Doron Rimar
Journal:  Clin Rev Allergy Immunol       Date:  2017-04       Impact factor: 8.667

8.  Meta-analysis of the changes of peripheral blood regulatory T cell to CD4+ T cell ratio in patients with systemic sclerosis.

Authors:  Chuiwen Deng; Wenli Li; Si Chen; Yongzhe Li
Journal:  Sci Rep       Date:  2017-03-02       Impact factor: 4.379

9.  Relationships of interleukin-10 with the regulatory T cell ratio and prognosis of cervical cancer patients.

Authors:  Beibei Wang; Haoyu Wang; Peiquan Li; Liangliang Wang; Hongli Liu; Jingbo Liu; Lihua Wang
Journal:  Clinics (Sao Paulo)       Date:  2018-12-03       Impact factor: 2.365

10.  Salivary psoriasin (S100A7) correlates with diffusion capacity of carbon monoxide in a large cohort of systemic sclerosis patients.

Authors:  Laura Giusti; Francesca Sernissi; Elena Donadio; Federica Ciregia; Camillo Giacomelli; Gino Giannaccini; Maria Rosa Mazzoni; Antonio Lucacchini; Laura Bazzichi
Journal:  J Transl Med       Date:  2016-09-08       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.